+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group

JAMA 276(2): 111-117

To compare the safety and efficacy of 2 doses of lamivudine given in combination with zidovudine with continued zidovudine monotherapy. Double-blind, randomized, multicenter, comparative trial of 223 patients treated for 24 weeks. Patients from 32 hospitals in Europe were enrolled throughout a 1-year period. Adult human immunodeficiency virus type 1 (HIV-1)-positive, zidovudine-experienced ( > or = 24 weeks prior zidovudine) patients with CD4+ cell counts between 0.10 and 0.40 x 10(9)/L (100-400 cells/microL). Patients received either 200 mg of zidovudine every 8 hours, 150 mg of lamivudine every 12 hours plus zidovudine, or 300 mg of lamivudine every 12 hours plus zidovudine for 24 weeks. All patients were then allowed to receive zidovudine and open-label lamivudine combination therapy. Twelve patients withdrew because of adverse events during the 24-week treatment period. Efficacy was measured by evaluating immunological and viral load changes, and safety was assessed by evaluating clinical manifestations and laboratory indexes of toxic effects. Patients receiving low- or high-dose combination therapy had greater treatment effects compared with patients receiving continued zidovudine monotherapy during the first 24 weeks as documented by changes in CD4+ cell counts (+0.04 vs +0.03 vs -0.02 x 10(9)/L, respectively; P < .001); log10 HIV-1 RNA as measured by the Roche assay (-0.96 vs -0.77 vs +0.07 copies/mL, respectively; P < .001) or log10 HIV-1 RNA measured by the quantitative nucleic acid sequence-based amplification assay (-0.59 vs -1.06 vs -0.02 copies/mL, respectively; P < .011); and immune-complex dissociated (ICD) p24 antigen (-74% vs -68% vs +27%, respectively; P < .001). There were no statistically significant differences in viral measurements, in CD4+ cell counts, or in safety profile between the groups receiving 2 doses of lamivudine in combination with zidovudine. The effects on CD4+ cell counts and ICD p24 antigen were sustained throughout 48 weeks for patients continuing combination therapy. Patients switching to combination therapy at week 24 showed improvement. In zidovudine-experienced HIV-1-infected patients, combination treatment with lamivudine and zidovudine is well tolerated and provides greater and more sustained increases in CD4+ cell counts and decreases in viral load than continued zidovudine monotherapy.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 047301415

Download citation: RISBibTeXText

PMID: 8656502

Related references

Safety and efficacy of isolated perfusion of extremities for recurrent tumor in elderly patients. Surgery 123(3): 335-343, 1998

Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients: A randomized controlled comparison with zidovudine monotherapy. JAMA (Journal of the American Medical Association) 276(2): 118-125, 1996

Safety and efficacy of kidney transplant biopsy: Tru-Cut needle vs sonographically guided Biopty gun. Ajr. American Journal of Roentgenology 160(2): 325-326, 1993

AVA, ACAC and PIAS. Australian Veterinary Journal 78(10): 673, 2000

AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group. Antiviral Therapy 4(2): 79-86, 1999

AVA: visual analysis of gene expression microarray data. Bioinformatics 19(2): 293-294, 2003

Triple nucleoside analogue antiretroviral therapy: expanding the treatment approaches for management of HIV infection. Expert Opinion on Investigational Drugs 8(8): 1147-1155, 1999

Profound and paradoxical impact on arthritis and autoimmunity of the rat antigen-presenting lectin-like receptor complex. Arthritis and Rheumatism 58(5): 1343-1353, 2008

Evolution of H5 subtype avian influenza A viruses in North America. Virus Research 51(2): 115-124, 1997

Emergence of crop seedlings in soils associated with bare patches beneath the canopy of the aromatic shrub Artemisia afra. Applied Plant Science 11(2): 35-38, 1997

Emergence of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 Variants, Viral Sequence Variation, and Disease Progression in Patients Receiving Antiretroviral Chemotherapy. The Journal of Infectious Diseases 177(6): 1506-1513, 1998

Dual requirement in yeast DNA mismatch repair for MLH1 and PMS1, two homologs of the bacterial mutL gene. Molecular and Cellular Biology 14(1): 407-415, 1994

A randomized, controlled trial of inSPOT and patient-delivered partner therapy for gonorrhea and chlamydial infection among men who have sex with men. Sexually Transmitted Diseases 38(10): 941-946, 2011

A six months follow up of diabetic myocardial infarction increased risk of congestive heart failure. Diabetologia 33(Suppl.): A90, 1990

Lamivudine is safe and effective in fulminant hepatitis B. Journal of Hepatology 30(3): 551, 1999